Ensysce Biosciences (ENSC) S-1/A 8 May 23 IPO registration (amended) Financial data

Cover

Cover	12 Months Ended
	Dec. 31, 2022
Entity Addresses [Line Items]
Document Type	S-1/A
Amendment Flag	true
Amendment Description	Amendment No. 1
Entity Registrant Name	ENSYSCE BIOSCIENCES, INC.
Entity Central Index Key	0001716947
Entity Tax Identification Number	82-2755287
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	7946 Ivanhoe Avenue
Entity Address, Address Line Two	Suite 201
Entity Address, City or Town	La Jolla
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92037
City Area Code	(858)
Local Phone Number	263-4196
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	7946 Ivanhoe Avenue
Entity Address, Address Line Two	Suite 201
Entity Address, City or Town	La Jolla
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92037
City Area Code	(858)
Local Phone Number	263-4196

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 3,147,702	$ 12,264,736
Unbilled receivable	276,821	441,721
Right-of-use asset	27,165	24,721
Prepaid expenses and other current assets	1,847,481	2,931,415
Total current assets	5,299,169	15,662,593
Property and equipment, net
Other assets	585,883	754,756
Total assets	5,885,052	16,417,349
Current liabilities:
Accounts payable	2,943,791	301,104
Accrued expenses and other liabilities	2,226,494	3,407,533
Lease liability	27,315	24,874
Notes payable and accrued interest ($4,063,431 and $12,358,886 at fair value at December 31, 2022 and 2021, respectively)	4,266,610	12,748,155
Total current liabilities	9,464,210	16,481,666
Long-term liabilities:
Notes payable, net of current portion (at fair value)	140,148	4,440,951
Other long-term liabilities	310,346	3,652,790
Total long-term liabilities	450,494	8,093,741
Total liabilities	9,914,704	24,575,407
Commitments and contingencies (Note 6)
Stockholders’ deficit
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at December 31, 2022 and December 31, 2021
Common stock, $0.0001 par value, 250,000,000 and 150,000,000 shares authorized at December 31, 2022 and December 31, 2021; 534,571 and 102,759 shares issued at December 31, 2022 and December 31, 2021, respectively; 534,490 and 102,678 shares outstanding at December 31, 2022 and December 31, 2021, respectively	53	10
Additional paid-in capital	107,216,566	77,967,314
Accumulated deficit	(110,931,063)	(85,845,567)
Total Ensysce Biosciences, Inc. stockholders’ deficit	(3,714,444)	(7,878,243)
Noncontrolling interests in stockholders’ deficit	(315,208)	(279,815)
Total stockholders’ deficit	(4,029,652)	(8,158,058)
Total liabilities and stockholders’ deficit	$ 5,885,052	$ 16,417,349

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Notes payable and accrued interest	$ 4,063,431	$ 12,358,886
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,500,000	1,500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	150,000,000
Common stock, shares issued	534,571	102,759
Common stock, shares outstanding	534,490	102,678

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Federal grants	$ 2,523,383	$ 3,531,199
Operating expenses:
Research and development	19,835,875	4,690,082
General and administrative	6,909,603	18,711,548
Total operating expenses	26,745,478	23,401,630
Loss from operations	(24,222,095)	(19,870,431)
Other income (expense):
Change in fair value of derivative liabilities		673,314
Loss on issuance of convertible notes	(3,609,944)
Issuance costs for convertible notes	(1,137,740)	(1,920,158)
Change in fair value of convertible notes	5,756,787	(2,993,060)
Issuance of liability classified warrants	(3,737,371)	(1,865,403)
Change in fair value of liability classified warrants	6,730,613	(1,438,186)
Loss on debt conversions	(3,964,633)	(154,391)
Interest expense, net	(109,525)	(1,295,307)
Other income and expense, net	86,223	(282,279)
Total other income (expense), net	14,410	(9,275,470)
Net loss	(24,207,685)	(29,145,901)
Net loss attributable to noncontrolling interests	(35,393)	(62,190)
Deemed dividend related to warrants down round provision	913,204	803,140
Net loss attributable to common stockholders	$ (25,085,496)	$ (29,886,851)
Net loss per basic and diluted share:
Net loss per share attributable to common stockholders, basic and diluted	$ (139.42)	$ (355.72)
Weighted average common shares outstanding, basic and diluted	179,925	84,018

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2020	$ 6	$ 49,517,908	$ (55,958,716)	$ (217,625)	$ (6,658,427)
Balance, shares at Dec. 31, 2020	65,703
Exercise of stock options		262,862			262,862
Exercise of stock options, shares	1,186
Settlement of convertible notes in business combination	$ 1	5,696,702			5,696,703
Settlement of convertible notes in business combination, shares	5,658
Conversion of convertible notes		2,247,615			2,247,615
Conversion of convertible notes, shares	1,614
Issuance of common stock for business combination, net of transaction costs	$ 3	7,695,261			7,695,264
Issuance of common stock for business combination, net of transaction costs, shares	28,517
Stock-based compensation		121,764			121,764
Issuance of warrants		11,565,472			11,565,472
Warrant modification		56,590			56,590
Deemed dividend related to warrants down round provision		803,140	(803,140)
Net loss			(29,083,711)	(62,190)	(29,145,901)
Balance at Dec. 31, 2021	$ 10	77,967,314	(85,845,567)	(279,815)	$ (8,158,058)
Balance, shares at Dec. 31, 2021	102,678
Exercise of stock options, shares
Conversion of convertible notes	$ 18	21,485,886			$ 21,485,904
Conversion of convertible notes, shares	181,999
Stock-based compensation		2,760,074			2,760,074
Deemed dividend related to warrants down round provision		913,204	(913,204)
Net loss			(24,172,292)	(35,393)	(24,207,685)
Consultant compensation		54,250			54,250
Consultant compensation, shares	208
Settlement of restricted stock units
Settlement of restricted stock units, shares	3,278
Settlement of payable to related parties	$ 1	191,617			191,618
Settlement of related party payable, Share	3,838
Capital contribution from related parties		608,382			608,382
Public offering, net	$ 24	3,783,216			3,783,240
Public offering, net, shares	241,666
Transaction costs associated with public offering		(547,377)			(547,377)
Reverse split fractional shares
Reverse split fractional shares, shares	823
Balance at Dec. 31, 2022	$ 53	$ 107,216,566	$ (110,931,063)	$ (315,208)	$ (4,029,652)
Balance, shares at Dec. 31, 2022	534,490

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (24,207,685)	$ (29,145,901)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		151
Gain on sale of asset	(4,500)
Accrued interest	60,488	349,339
Accretion of discounts on promissory notes		945,969
Change in fair value of derivative liability		(673,314)
Change in fair value of convertible notes	(5,756,787)	2,993,060
Loss on issuance of convertible notes	3,609,944
Loss on extinguishment of debt		347,566
Stock-based compensation	1,071,843	121,764
Issuance of liability classified warrants	3,737,371	1,865,403
Change in fair value of liability classified warrants	(6,730,613)	1,438,186
Issuance of warrants for share subscription facility		11,565,472
Commitment fee for share subscription facility		1,124,289
Warrant modification		56,590
Lease cost	(3)	(1,808)
Issuance costs for convertible notes	946,085	1,920,158
Loss on debt conversions	3,964,633	154,391
Other income	(60,035)
Changes in operating assets and liabilities:
Unbilled receivable	164,900	(441,721)
Prepaid expenses and other assets	1,652,756	(1,616,019)
Accounts payable	2,642,686	(1,423,494)
Accrued expenses and other liabilities	1,021,478	2,177,742
Net cash used in operating activities	(17,887,439)	(8,242,177)
Cash flows from investing activities:
Proceeds from sale of assets	4,500
Net cash provided by investing activities	4,500
Cash flows from financing activities:
Proceeds from public offering, net	3,783,240
Proceeds from issuance of convertible notes, net	7,533,915	14,029,842
Proceeds from issuance of promissory notes to related parties		350,000
Repayment of convertible notes	(1,408,364)
Repayment of promissory notes		(467,774)
Transaction costs from public offering	(547,377)
Proceeds from exercise of stock options		262,862
Proceeds from issuance of common stock for business combination, net of transaction costs		6,626,312
Repayment of financed insurance premiums	(595,509)	(488,543)
Net cash provided by financing activities	8,765,905	20,312,699
Decrease (increase) in cash and cash equivalents	(9,117,034)	12,070,522
Cash and cash equivalents beginning of period	12,264,736	194,214
Cash and cash equivalents end of period	3,147,702	12,264,736
Supplemental cash flow information:
Income tax payments	1,600	1,600
Supplemental disclosure of non-cash investing and financing activities:
Stock-based compensation	1,742,481
Fair value of derivative liability at issuance		3,052
Settlement of convertible notes into common stock	17,521,271	7,789,927
Payable to related parties settled in shares	191,618
Capital contribution from related parties	608,382
Net assets acquired in business combination		1,068,950
Financed insurance premiums	399,949	867,300
Share subscription facility transaction costs		12,689,764
Deemed dividend related to warrants down round provision	$ 913,204	$ 803,140

ORGANIZATION AND PRINCIPAL ACTI

ORGANIZATION AND PRINCIPAL ACTIVITIES	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
ORGANIZATION AND PRINCIPAL ACTIVITIES	NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES Ensysce Biosciences, Inc. (“Ensysce”), along with its subsidiary, EBIR, Inc. (“EBIR”, formerly known as Covistat, Inc.) and its wholly owned subsidiaries EBI Operating, Inc. and EBI OpCo. Inc. (collectively, the “Company”) is engaged in the development of drug delivery platforms targeting pain and cancer markets. The primary focus of the Company is its program developing abuse and overdose resistant pain technology with a clinical stage program being the abuse resistant, TAAP (Trypsin Activated Abuse Protection) opioid product candidate, PF614. In addition, the Company is developing its MPAR TM TM On January 31, 2021, Leisure Acquisition Corp., a Delaware corporation (“LACQ”), entered into an Agreement and Plan of Merger (as amended, the “Merger Agreement”) with Ensysce Biosciences, Inc., a Delaware corporation (“Former Ensysce”), and EB Merger Sub, Inc., a Delaware corporation and wholly owned, direct subsidiary of LACQ (“Merger Sub”). Pursuant to the Merger Agreement, on June 30, 2021 (the “Closing Date”), Merger Sub was merged with and into Former Ensysce, with Former Ensysce surviving the merger (“Merger” and, together with the other transactions contemplated by the Merger Agreement, the “Business Combination”). In connection with the closing of the Business Combination on the Closing Date (the “Closing”), Former Ensysce became a wholly owned subsidiary of LACQ and the stockholders of Former Ensysce, as of immediately prior to the effective time of the Merger, received shares of LACQ and hold a portion of the shares of Common Stock, par value $ 0.0001 On the Closing Date, at the effective time of the Merger, LACQ changed its name from “Leisure Acquisition Corp.” to “Ensysce Biosciences, Inc.” Unless the context otherwise requires, “we,” “us,” “our” and the “Company” refer to Ensysce and the combined company and its subsidiaries following the Closing. Unless the context otherwise requires, references to “LACQ” refer to Leisure Acquisition Corp., a Delaware corporation, prior to the Closing. In connection with the Business Combination, outstanding shares of common stock of Former Ensysce (including shares resulting from the conversion of Former Ensysce’s convertible debt prior to Closing) were converted into the right to receive shares of Ensysce at an exchange ratio of 0.06585 71.8 In June 2020, the Company commenced an initiative to develop a therapeutic for the treatment of certain coronavirus infections through the formation of a separate entity, EBIR, a Delaware corporation. Pursuant to the articles of incorporation, EBIR was authorized to issue 1,000,000 shares of common stock, $ 0.001 par value per share, and 100,000 shares of preferred stock, $ 0.001 par value per share. Ensysce is a 79.2 % stockholder in EBIR, with 19.8 % and 1.0 % of the shares held by certain key personnel of the Company and an unrelated party, respectively. The Company currently operates in one business segment, which is pharmaceuticals. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer. Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements

BASIS OF PRESENTATION

BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 2 – BASIS OF PRESENTATION The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the United States Securities Exchange Commission (“SEC”). The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation. Reverse Stock Split In October 2022, the Company completed a 1-for-20 reverse split Business Combination The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, LACQ was identified as the acquired company for financial reporting purposes, primarily because the stockholders of Former Ensysce control the majority of the voting power of the combined company, Former Ensysce’s board of directors comprise a majority of the governing body of the combined company, and Former Ensysce’s senior management comprise the leadership of the combined company. Accordingly, for accounting purposes, the transaction was treated as the equivalent of Former Ensysce issuing shares for the net assets of LACQ, accompanied by a recapitalization. The net assets of LACQ, primarily consisting of cash of $ 7.8 1.1 0.06585 Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any product revenue and had an accumulated deficit of $ 110.9 In December 2020, the Company executed the GEM Agreement. Under the agreement, the investor agreed to provide the Company with a share subscription facility of up to $ 60.0 million for a 36-month term following the public listing of the Company’s common stock. The Company controls the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation. The investor will pay, in cash, a per-share amount equal to 90% of the average daily closing price of the Company’s stock during the 30 consecutive trading days prior to the issuance of a draw notice, which shall not exceed 400% of the average trading volume for the 30 trading days immediately preceding the draw down date. On June 30, 2021, the Company consummated the Business Combination, resulting in the Company’s shares becoming publicly listed on Nasdaq on July 2, 2021. Concurrent with the public listing of the Company’s shares, the Company issued to the investor 4,608 warrants with a five-year term to purchase common stock of Ensysce at an exercise price of $ 2,402.40 per share, subsequently reduced to $ 16.80 at December 31, 2022 (Note 8). The Company is required to pay a commitment fee to the investor of $ 1.2 million with $ 0.8 million due on the first anniversary of the public listing date and $ 0.4 million due on the 18-month anniversary of the public listing date. The first $ 0.8 million of the commitment fee was paid in July 2022 in freely tradable common stock of the Company (Note 10) and the remaining $ 0.4 million due in January 2023 was paid in freely tradable common stock of the Company. Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements In July and August 2022, the Company received funding under a $ 8.48 million convertible note financing agreement with the same institutional investors (the “2022 Notes”) (See Note 7 for additional information). The agreement limits the Company’s ability to execute certain debt and equity financings, including under the GEM Agreement, while the convertible notes are outstanding. Without the availability of proceeds through the GEM Agreement, existing cash resources are not sufficient to fund current planned operations. While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued. The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates and Assumptions Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain accrued research and development services, the valuation allowance of deferred tax assets resulting from net operating losses, and the fair value of warrants and options to purchase the Company’s common stock and convertible notes payable. Cash and Cash Equivalents For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Concentrations of Credit Risk and Off-Balance Sheet Risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts currently exceed federally insured limits. The Company has no financial instruments with off-balance sheet risk of loss. Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements Property and Equipment Property and equipment include office and laboratory equipment that is recorded at cost and depreciated using the straight-line method over the estimated useful lives of five six years 0 151 Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for the year ended December 31, 2022 and 2021. Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including notes payable, to determine whether such instruments are derivatives or contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract and the features of the derivatives. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheet. Fair Value Measurement ASC 820, Fair Value Measurements The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company. As of December 31, 2022 and 2021, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items. 2021 Notes In 2021 the Company issued convertible notes with a face value of $ 15.9 2022 Notes In July 2022 the Company issued convertible notes with a face value of $ 8.5 Distinguishing Liabilities from Equity, Warrants In 2021 the Company issued liability classified warrants in connection with the issuance of the 2021 Notes. In 2022 the Company issued liability classified warrants in connection with the issuance of the 2022 Notes. The warrants were liability classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8 for details of the warrants. The following tables present assets and liabilities measured and recorded at fair value on the Company’s consolidated balance sheet as of December 31, 2022 and 2021. As of December 31, 2021, all contingent put options, associated with the pre-combination convertible notes, were settled upon conversion of the notes at the closing of the Business Combination. SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE Total Level 1 Level 2 Level 3 December 31, 2022 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 4,203,579 $ - $ - $ 4,203,579 Liability classified warrants 310,346 310,346 Total $ 4,513,925 $ - $ - $ 4,513,925 Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements Total Level 1 Level 2 Level 3 December 31, 2021 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 16,799,837 $ - $ - $ 16,799,837 Liability classified warrants 3,303,588 - - 3,303,588 Total $ 20,103,425 $ - $ - $ 20,103,425 The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities for the year ended December 31, 2022: SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 For the year ended December 31, 2022 Total Convertible note Liability classified warrants Fair value, December 31, 2021 $ 20,103,425 $ 16,799,837 $ 3,303,588 Additions, net 12,217,371 8,480,000 3,737,371 Conversions/payments (18,929,415 ) (18,929,415 ) - Loss on issuance of convertible notes 3,609,944 3,609,944 - Change in fair value (12,487,400 ) (5,756,787 ) (6,730,613 ) Fair value, December 31, 2022 $ 4,513,925 $ 4,203,579 $ 310,346 Federal Grants In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse awarded the Company a research and development grant related to the development of its MPAR TM 5.4 3.2 2.2 1.1 5.1 2.1 3.0 2.8 2.8 10.7 In September 2019, the NIH/National Institute on Drug Abuse awarded the Company a second research and development grant related to the development of its TAAP/MPAR TM 5.4 The Company recognizes revenue when costs related to the grants are incurred. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with The revenue recognized under the MPAR Grant and OUD Grant was as follows: SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS 2022 2021 Year Ended December 31, 2022 2021 MPAR $ 2,006,885 $ 2,646,579 TAAP/OUD 516,498 884,620 Total $ 2,523,383 $ 3,531,199 Revenue $ 2,523,383 $ 3,531,199 Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation allowances are recorded. Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements Immaterial Correction of an Error In August 2022, the Company concluded that there was an error in the measurement of the unbilled receivable as of December 31, 2021. The error was corrected in the second quarter of 2022. The change resulted in a decrease in the balance of the unbilled receivable of $ 214,308 The Company, in consultation with the Audit Committee of the Board of Directors, evaluated the effect of these adjustments on the Company’s consolidated financial statements under ASC 250, Accounting Changes and Error Corrections and Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements and determined it was not necessary to recall its previously issued consolidated financial statements as the errors did not materially misstate any previously issued consolidated financial statements and the correction of the error in the current fiscal year is also not material. The Company looked at both quantitative and qualitative characteristics of the required corrections in making the determination. Research and Development Costs The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. General and Administrative Expenses General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees. Stock-based Compensation The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. For the year ended December 31, 2022 and 2021, stock-based compensation costs are recorded in research and development and general and administrative expenses in the consolidated statements of operations. From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying equity awards. Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements Earnings per Share The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the Company’s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding during the period, determined using the treasury stock method and the average stock price during the period. A reconciliation of the numerators and denominators of the basic and diluted earnings per share calculations follows: SCHEDULE OF EARNINGS PER SHARE RECONCILIATION 2022 2021 Year Ended December 31, 2022 2021 Numerator: Net income (loss) attributable to common stockholders $ (25,085,496 ) $ (29,886,851 ) Denominator: Weighted average shares outstanding, basic and diluted 179,925 84,018 Net loss per share attributable to common stockholders, basic and diluted $ (139.42 ) $ (355.72 ) The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price for the Convertible Notes for the purposes of the weighted average share calculation below): SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES 2022 2021 Year Ended December 31, 2022 2021 Stock options 26,302 18,742 RSUs 3,772 - Warrants 138,485 42,807 Convertible Notes 73,326 2,533 Total 241,885 64,082 Anti-dilutive weighted average shares 241,885 64,082 Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance is effective for fiscal years beginning after December 31, 2021 and interim periods within that year. Early adoption is permitted. The Company adopted the guidance in 2022 and it did not have a material impact on the financial statements due to their current tax position. In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Topic 470) to address issues identified as a result of the complexity with applying GAAP for certain financial instruments with characteristics of liabilities and equity. The FASB decided to reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Certain types of convertible instruments will continue to be subject to separation models: (a) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (b) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. For convertible instruments, the contracts primarily affected are those with beneficial conversions or cash conversion features as the accounting models for those specific features have been removed. For contracts in an entity’s own equity, the contracts primarily affected are freestanding instruments and embedded features that are accounted for as derivatives due to a failure to meet the settlement conditions of the derivatives scope exceptions. The FASB simplified the settlement assessment by removing the requirements to (a) consider whether the contract would be settled in registered shares, (b) to consider whether collateral is required to be posted, and (c) assess shareholder rights. The FASB also decided to enhance information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023 and early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company will adopt the standard with an effective date of January 1, 2023 and it is not expected to have a material impact on currently recorded transactions. In May 2021, the FASB issued ASU No. 2021-04, Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (A Consensus of the FASB Emerging Issues Task Force (the “EITF”)) – to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. Under the amendments, an issuer should measure the effect of a modification as the difference between the fair value of the modified warrant and the fair value of that warrant immediately before modification. The EITF concluded that the recognition of the modification depends on the nature of the transaction in which a warrant is modified. If there is more than one element in a transaction (for example, if the modification involves both a debt modification and an equity issuance), then the guidance requires the issuer to allocate the effect of the option modification to each element. On January 1, 2022, the Company adopted ASU 2021-04 and the adoption did not have a significant impact on the consolidated financial statements. Reclassification of prior year presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. An adjustment has been made to the consolidated statement of operations for the year ended December 31, 2021, to reclassify the loss on debt conversions. Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	12 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 4 – PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS 2022 2021 December 31, 2022 2021 Prepaid research and development $ 1,300,473 $ 2,124,008 Prepaid insurance 445,583 733,234 Other prepaid expenses 101,425 74,173 Total prepaid expenses and other current assets $ 1,847,481 $ 2,931,415

ACCRUED EXPENSES AND OTHER LIAB

ACCRUED EXPENSES AND OTHER LIABILITIES	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER LIABILITIES	NOTE 5 – ACCRUED EXPENSES AND OTHER LIABILITIES Accrued expenses and other liabilities consisted of the following: SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES 2022 2021 December 31, 2022 2021 Accrued research and development $ 1,332,713 $ 388,997 Share subscription facility commitment fees 400,000 800,000 Professional fees 421,530 138,086 Other accrued liabilities 72,251 67,939 Accrued scientific advisory board fees - 60,032 Consultant fees - 1,342,479 Bonus Accrual - 610,000 Total accrued expenses and other liabilities $ 2,226,494 $ 3,407,533 Other long-term liabilities consisted of the following: SCHEDULE OF OTHER LONG-TERM LIABILITIES 2022 2021 December 31, 2022 2021 Share subscription facility commitment fees $ - $ 349,202 Liability classified warrants 310,346 3,303,588 Total other long-term liabilities $ 310,346 $ 3,652,790 Other long-term liabilities $ 310,346 $ 3,652,790 Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 6 – COMMITMENTS AND CONTINGENCIES Purchase Commitments As of December 31, 2022, the Company’s commitments included an estimated $ 21.6 Litigation As of December 31, 2022 and 2021, there were no pending legal proceedings against the Company that are expected to have a material adverse effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation. Lease The Company’s current lease agreement (as amended) has a term that extends through October 31, 2023 with no option to renew. As of December 31, 2022, the future lease payments totaled $ 27,316 . The Company recognized total rent expense of $ 31,756 and $ 41,418 in the years ended December 31, 2022, and 2021, respectively. Compensation Commitments In assessing performance for 2022 annual bonuses, the Board of Directors established achievement of 2022 goals at 75 0.4 Compensation Subject to Shareholder Approval In July 2021, the Company engaged two consultants to perform certain public and investor relations services in consideration for warrants to purchase 2,083 1,507.20 208 833 one year 50 1,342,479 Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 7 – NOTES PAYABLE The following table provides a summary of the Company’s outstanding debt as of December 31, 2022: SCHEDULE OF DEBT Principal balance Accrued interest Fair value adjustment Net debt balance 2022 Notes $ 3,905,264 $ 10,544 $ 287,771 $ 4,203,579 Financed insurance 195,273 7,906 - 203,179 Total $ 4,100,537 $ 18,450 $ 287,771 $ 4,406,758 The following table provides a summary of the Company’s outstanding debt as of December 31, 2021: Principal balance Accrued interest Unamortized debt discount Net debt balance 2021 Notes $ 13,647,341 $ 159,435 $ 2,993,061 $ 16,799,837 Financed insurance 385,187 4,082 - 389,269 Total $ 14,032,528 $ 163,517 $ 2,993,061 $ 17,189,106 The interest expense recognized for notes payable (excluding the 2022 and 2021 Notes) was as follows: SCHEDULE OF INTEREST EXPENSE DEBT 2022 2021 Year Ended December 31, 2022 2021 Stated interest accrual $ 9,909 $ 251,857 Debt discount amortization - 945,969 Total $ 9,909 $ 1,197,826 2021 Notes On September 24, 2021, the Company entered into an agreement with institutional investors to issue the 2021 Notes. The agreement provides for two closings: the first closing for $ 5.3 4.6 10.6 9.4 The proceeds of the sale of the securities shall be used for working capital purposes subject to certain customary restrictions and secured by the Company’s rights to its patents and licenses. The Company may not issue any additional debt or equity without the prior written consent of the holders. The 2021 Notes mature on June 23, 2023 August 4, 2023 5 6 The Company elected to apply the fair value option to the measurement of the 2021 Notes. The total initial fair value of the debt at issuance was $ 15.9 1.9 1.0 0.9 8 0.2 After multiple conversions (at original contract terms and at amended reduced conversion prices) since issuance the Company recognized a change in fair value of convertible notes of $ 2.7 million (gain) for the period ended December 31, 2022 primarily due to reductions in the Company’s stock price. Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements The following table provides a summary of the Company’s 2021 Note conversions during the year ended December 31, 2022: SCHEDULE OF CONVERSION DEBT Shares Weighted Average Conversion Price Conversion Value During the year ended December 31, 2022 70,773 $ 191.06 $ 13,521,834 On August 8, 2022, the parties agreed to modify the conversion price of the remaining 2021 Notes from $ 187.20 84.00 84.00 55.20 4.0 1.0 0.4 2022 Notes On June 30, 2022, the Company entered into an $ 8.0 4.24 4.0 On the issuance date, the Company assessed the probability of the potential settlement scenarios under the terms of the 2022 Notes and determined that the predominant settlement feature of the 2022 Notes was the redemption feature into shares of the Company’s common stock issuable at the lower of the conversion price or 92 10 The Company recorded the 2022 Notes at an initial fair value of $ 12.09 3.6 1.1 6 0.5 0.6 3.1 The December 31, 2022 fair value measurement includes the assumption of accrued interest and interest expense (at the stated rate plus an 8 0.2 The 2022 Notes are convertible into common stock, at a per share conversion price equal to $ 130.80 10 th The Company may elect to pay all or part of the redemption amount in cash with a premium of 8% or in conversion shares of common stock based on a conversion price equal to the lesser of (i) the conversion price and (ii) 92% of the average of the three lowest VWAPs (as defined) during the ten consecutive trading days ending on the trading day that is immediately prior to the applicable redemption date, but in no event may the Company pay the redemption amount in conversion shares of common stock unless the conversion price is at least equal to $24.072 and the Company has been in compliance with customary requirements under the agreement, unless waived in writing by the holder. In connection with each of the first and second closings of the 2022 Notes the Company also issued warrants to purchase 19,447 170.04 30 five years 187.20 The proceeds of the 2022 Notes will be used for working capital purposes subject to certain customary restrictions are secured by the Company’s rights to its patents and licenses. The Company is restricted from issuing certain additional debt or equity without the prior written consent of the holders for certain specified periods set forth in the 2022 Notes. If, at any time while the 2022 Notes are outstanding, the Company carries out one or more capital raises in excess of $ 5.0 20 8 The 2022 Notes mature on December 29, 2023 February 7, 2024 6 6 The following table provides a summary of the Company’s 2022 Notes conversions during the year ended December 31, 2022: SCHEDULE OF CONVERSION DEBT Weighted Average Conversion Shares Conversion Price Value During the year ended December 31, 2022 111,226 $ 36.06 $ 4,011,035 Financed Insurance Premiums During the year ended December 31, 2022, the Company financed its directors’ and officers’ liability insurance in the amount of $ 399,949 203,179 9,402 7,905

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 8 – STOCKHOLDERS’ EQUITY In June 2021, in connection with the Business Combination, the Company amended and restated its Certificate of Incorporation to authorize 150,000,000 1,500,000 0.0001 250,000,000 no Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements Common Stock On June 30, 2021, in connection with the Business Combination, the following common stock activity occurred: ● 66,889 ● 25,913 ● 5,658 5.8 ● 81 ● 2,083 ● 520 On December 9, 2022, the Company completed a public offering for the sale of 241,666 shares of common stock at $ 16.80 per share for gross proceeds of $ 4.1 million, net of $ 0.3 million in underwriting fees. In addition, the Company issued 549,987 warrants with an exercise price of $ 16.80 per share that expire five years following the date of issuance. In connection with the public offering, the Company incurred approximately $ 0.5 million in transaction costs that are recognized in the consolidated statement of changes in stockholders’ deficit. Warrants On December 31, 2022, outstanding warrants to purchase shares of common stock are as follows: SCHEDULE OF OUTSTANDING WARRANT Reference Shares Underlying Outstanding Warrants Exercise Price Description Classification (a) 70,969 $ 2,400 .00– 2,760.00 LACQ warrants Equity (b) 4,608 $ 8.58 Share subscription facility Equity (c) 4,512 $ 187.20 2021 Notes Liability (d) 38,894 $ 24.07 2022 Notes Liability (e) 549,987 $ 16.80 Public offering Equity 668,970 a) On June 30, 2021, as a result of the Closing, the Company assumed a total of 78,751 7,782 2,400.00 2,760.00 June 30, 2026 41,666 29,303 On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the price of 2,083 2,760.00 2,400.00 56,590 b) On July 2, 2021, upon public listing of the Company’s shares, the Company issued 4,608 three 2,402.40 3,477.60 11.6 Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements The warrants have been subject to multiple exercise price reductions as required by a down round adjustment feature of the warrant, due to common stock issued at a price below the then current exercise price (primarily the result of the conversions of the 2021 Notes and the 2022 Notes). The adjustments have progressed from the original exercise price of $2,402.40 16.80 c) On September 24, 2021 and November 5, 2021, the Company issued 1,504 3,008 1,831.20 September 23, 2026 187.20 d) On July 1, 2022 and August 9, 2022, the Company issued 19,447 170.04 June 29, 2027 August 8, 2027 e) On December 9, 2022, the Company issued 549,987 16.80 December 9, 2027 The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows: SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS Stock price Exercise price Expected term (years) Volatility Risk free rate (a) LACQ warrants (grant date varies) 3,477.60 2,400.00 - 2,760.00 3.00 110.0 % 0.5 % (b) Share subscription facility (grant date 7/2/21) 3,477.60 2,402.40 3.00 110.0 % 0.5 % (b) Share subscription facility (remeasurement date varies) 1 4.40 - 1,029.60 16.80 - 1,080.00 1.56 - 2.49 108.2 125.3 % 1.0 4.5 % (c) Liability classified warrants (grant date 9/24/21) 1,077.60 1,831.20 5.00 94.1 % 1.0 % (c) Liability classified warrants (grant date 11/5/21) 540.00 1,831.20 5.00 94.1 % 1.0 % (c) Liability classified warrants (remeasured at 12/31/22) 9.36 187.20 3.75 - 3.85 140.9 141.1 % 4.2 % (d) Liability classified warrants (grant date 7/1/22) 136.80 170.04 5.00 98.9 % 2.9 % (d) Liability classified warrants (grant date 8/9/22) 127.20 170.04 5.00 102.8 % 3.0 % (d) Liability classified warrants (remeasured at 12/31/22) 9.36 24.12 4.50 - 4.61 138.0 139.4 % 4.0 %

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	NOTE 9 - STOCK-BASED COMPENSATION In 2016, Former Ensysce adopted the Ensysce Biosciences, Inc. 2016 Stock Incentive Plan (the “2016 Plan”). The 2016 Plan, as amended, allowed for the issuance of non-statutory stock options, incentive stock options and other equity awards to Former Ensysce’s employees, directors, and consultants. In March 2019, Former Ensysce adopted the 2019 Directors Plan, which was amended in August 2020. The 2019 Directors Plan, as amended, allowed for the issuance of shares of Former Ensysce’s common stock pursuant to the grant of non-statutory stock options. In addition to the 2016 Plan and the 2019 Directors Plan, the Company has two legacy equity incentive plans (the “Legacy Plans”). No additional equity awards may be made under the Legacy Plans and the outstanding options will expire if unexercised by certain dates through August 2024. In connection with the Business Combination, the Company assumed the 2021 Omnibus Incentive Plan (the “2021 Omnibus Plan”), which was approved by LACQ’s board and subsequently LACQ’s stockholders at a special stockholder meeting on June 28, 2021. The 2021 Omnibus Plan provides for the conversion with existing terms of the 18,432 4,166 12,500 The Company recognized within general and administrative expense stock-based compensation expense of $ 919,056 121,764 152,787 0 Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements Option Activity During the year ended December 31, 2022, the Company granted stock options to purchase an aggregate of 114,550 zero four years 8.50 125.60 The following table summarizes the Company’s stock option activity during the year ended December 31, 2022: SCHEDULE OF STOCK OPTION ACTIVITY Weighted average Options Exercise price Remaining contractual life Intrinsic value Outstanding at December 31, 2021 18,505 $ 576.70 6.00 $ 10,207,306 Granted 9,535 928.11 8.34 - Exercised - - - - Expired / Forfeited (1,706 ) 519.62 - - Outstanding at December 31, 2022 26,334 707.63 6.53 - Exercisable at December 31, 2022 23,258 738.89 6.19 - Vested and expected to vest 26,334 707.63 6.53 - Option Valuation The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (there were no grants issued in 2021): SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS December 31, 2022 Exercise price $ 102.00 1,507.20 Expected stock price volatility 76.61 95.87 % Expected term (years) 5.19 10.00 Risk-free interest rate 1.52 3.14 % Expected dividend yield 0 % ● Expected stock-price volatility. ● Expected term. ● Risk-free interest rate. ● Expected dividend yield. Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements The weighted-average grant date fair value of options granted during the year ended December 31, 2022 was $ 230.89 As of December 31, 2022, the Company had an aggregate of $ 361,863 1.61 Restricted Stock Units The following table summarizes the Company’s restricted stock units activity during the year ended December 31, 2022: SCHEDULE OF RESTRICTED STOCK UNITS Restricted Stock Units Weighted average fair value Outstanding at December 31, 2021 - $ - Granted 5,320 215.22 Released (3,485 ) 294.29 Cancelled (832 ) - Outstanding at December 31, 2022 1,003 $ 120.02 The remaining awards outstanding are subject to time-based vesting conditions and are scheduled to vest by December 2023. The estimated fair value of each of the Company’s restricted stock unit awards was determined on the date of grant based on the closing price of the Company’s common stock on the previous trading date. Shares Reserved for Future Issuance The following shares of common stock are reserved for future issuance: SCHEDULE OF COMMON STOCK FUTURE ISSUANCE December 31, 2022 Awards outstanding under the 2021 Omnibus Incentive Plan 27,337 Awards available for future grant under 2021 Omnibus Incentive Plan 4,569 2022 Notes outstanding 162,232 Warrants outstanding 668,970 Total shares of common stock reserved for future issuance 863,108

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2022
Ensysce Biosciences, Inc [Member]
INCOME TAXES	NOTE 10 - INCOME TAXES Loss before provision for income taxes consisted of the following: SCHEDULE OF INCOME TAXES BENEFIT Year ending December 31, 2022 2021 United States $ (24,207,685 ) $ (29,145,901 ) The federal and state income tax provision (benefit), included in general and administrative expenses in the Consolidated Statement of Operations, is summarized as follows: SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT) Year ending December 31, 2022 2021 Current state provision - $ 1,600 Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows: SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION Year ending December 31, 2022 2021 Income (benefit) taxes at statutory rates (5,083,614 ) (6,120,640 ) State income tax, net of federal benefit (175,164 ) (131,962 ) Warrants and convertible debt (234,214 ) 1,620,341 Nondeductible executive compensation - 480,248 Stock based compensation 303,499 (278,940 ) Share subscription facility transaction costs 20,335 2,664,850 Research and development tax credits (1,028,988 ) (501,451 ) Change in tax rates 54,263 371,784 Other (78,227 ) (139,213 ) Change in valuation allowance 6,222,110 2,034,983 Total - - Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards. The Company’s deferred tax assets were comprised of the following: SCHEDULE OF DEFERRED TAX ASSETS As of December 31, 2022 2021 Deferred tax assets: Net operating loss tax carryforwards $ 26,726,066 $ 25,068,127 Tax credits 4,164,187 3,164,799 Capitalized research costs 3,729,483 - Stock-based compensation 1,173,158 915,675 Other 265,677 687,422 Deferred Tax Assets, Gross 36,058,571 29,836,023 Valuation allowance (36,052,644 ) (29,830,534 ) Total deferred tax assets 5,927 5,489 Deferred tax liabilities: Convertible notes: embedded derivatives - - Other (5,927 ) (5,489 ) Total deferred tax liabilities (5,927 ) (5,489 ) Net deferred tax assets $ - $ - As of December 31, 2022, the Company had federal and California net operating loss (NOL) carryforwards of $ 102.9 million and $ 73.2 million, respectively, net of the NOLs that will expire due to Internal Revenue Code (IRC) Section 382 limitations. The federal net operating losses generated in 2018 and after of $ 20.5 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year. The federal net operating losses generated prior to 2018 of $ 82.4 million will begin to expire in 2026 unless previously utilized. The California NOL carryforwards will begin to expire in 2028, unless previously utilized. Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements In addition, as of December 31, 2022, the Company had federal and state research and development (R&D) tax credit carryforwards of $ 4.2 1.7 Pursuant to IRC Sections 382 and 383, annual use of the Company’s NOL and R&D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. Although the Company has not completed an IRC Section 382/383 analysis regarding the limitation of NOL and R&D credit carryforwards as of December 31, 2022, the Company estimates that approximately $ 1.5 The following table summarizes the activity related to the Company’s unrecognized tax benefits: SUMMARY OF INCOME TAX CONTINGENCIES Year ending December 31, 2022 2021 Balance at beginning of year 1,135,179 968,445 Increases related to current year tax positions 341,108 171,977 Decreases related to prior year tax positions (48,026 ) (5,243 ) Balance at end of year 1,428,261 1,135,179 As of December 31, 2022 and 2021, the Company had unrecognized tax benefits of $ 1.4 1.1 no The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2019 and state and local income tax examinations before 2018. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not currently under examination by the Internal Revenue Service or any state or local tax authority. Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements

RELATED PARTIES

RELATED PARTIES	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 11 - RELATED PARTIES The Company paid cash compensation during the year ended December 31, 2022 and 2021 of $ 0 30,909 0 12,989 The Company issued a series of convertible notes to the Chairman of the Board as described in Note 7, which totaled $ 2.5 million as of December 31, 2020. All outstanding notes and accrued interest converted into common stock upon the closing of the Business Combination on June 30, 2021. In July 2022, the Chief Executive Officer and a Board member transferred 3,838 0.8 3,838 On December 9, 2022, the Company completed a public offering for the sale of 241,666 16.80 549,987 16.80 29,761 59,523

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 - SUBSEQUENT EVENTS On January 3, 2023, the Company issued 44,444 400,000 On January 12, 2023, the Company entered into a Letter Agreement to reduce the conversion price for the remaining balance of the Company’s outstanding 2022 Notes from $ 24.072 9.0144 0.4 3.1 0.4 0.6 On January 31, 2023, the Board of Directors declared a dividend of 0.012 of a share of Series A Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company’s common stock to stockholders of record on February 13, 2023. Each full share of the Series A Preferred Stock entitles holders to 1,000,000 votes per share with respect to the reverse stock split proposal and the adjournment proposal at the Company’s special meeting of stockholders on March 23, 2023. The Series A Preferred Stock has no dividend rights and is subject to full redemption following the effectiveness of a reverse stock split. The Series A Preferred Stock was registered through a Certificate of Designation filed with the State of Delaware on February 1, 2023. On February 2, 2023, the Company agreed to issue and sell in a registered direct offering an aggregate of 297,619 10.08 3.0 February 6, 2023 8.58 297,619 20,832 12.60 five years On March 23, 2023, at a special meeting of stockholders, the Company’s stockholders approved a proposal to authorize the Company’s Board of Directors to complete a reverse stock split at a ratio of not less than one-for-five and not more than one-for-twelve. On March 31, 2023, the Company completed a one-for-twelve reverse split of its outstanding common stock

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Use of Estimates and Assumptions	Use of Estimates and Assumptions Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain accrued research and development services, the valuation allowance of deferred tax assets resulting from net operating losses, and the fair value of warrants and options to purchase the Company’s common stock and convertible notes payable.
Cash and Cash Equivalents	Cash and Cash Equivalents For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
Concentrations of Credit Risk and Off-Balance Sheet Risk	Concentrations of Credit Risk and Off-Balance Sheet Risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts currently exceed federally insured limits. The Company has no financial instruments with off-balance sheet risk of loss. Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements
Property and Equipment	Property and Equipment Property and equipment include office and laboratory equipment that is recorded at cost and depreciated using the straight-line method over the estimated useful lives of five six years 0 151 Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company will recognize an impairment loss only if the carrying amount is not recoverable through its undiscounted cash flows and measure any impairment loss based on the difference between the carrying amount and estimated fair value. There were no such losses for the year ended December 31, 2022 and 2021.
Derivative Financial Instruments	Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including notes payable, to determine whether such instruments are derivatives or contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract and the features of the derivatives. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheet.
Fair Value Measurement	Fair Value Measurement ASC 820, Fair Value Measurements The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company. As of December 31, 2022 and 2021, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items. 2021 Notes In 2021 the Company issued convertible notes with a face value of $ 15.9 2022 Notes In July 2022 the Company issued convertible notes with a face value of $ 8.5 Distinguishing Liabilities from Equity, Warrants In 2021 the Company issued liability classified warrants in connection with the issuance of the 2021 Notes. In 2022 the Company issued liability classified warrants in connection with the issuance of the 2022 Notes. The warrants were liability classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8 for details of the warrants. The following tables present assets and liabilities measured and recorded at fair value on the Company’s consolidated balance sheet as of December 31, 2022 and 2021. As of December 31, 2021, all contingent put options, associated with the pre-combination convertible notes, were settled upon conversion of the notes at the closing of the Business Combination. SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE Total Level 1 Level 2 Level 3 December 31, 2022 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 4,203,579 $ - $ - $ 4,203,579 Liability classified warrants 310,346 310,346 Total $ 4,513,925 $ - $ - $ 4,513,925 Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements Total Level 1 Level 2 Level 3 December 31, 2021 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 16,799,837 $ - $ - $ 16,799,837 Liability classified warrants 3,303,588 - - 3,303,588 Total $ 20,103,425 $ - $ - $ 20,103,425 The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities for the year ended December 31, 2022: SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 For the year ended December 31, 2022 Total Convertible note Liability classified warrants Fair value, December 31, 2021 $ 20,103,425 $ 16,799,837 $ 3,303,588 Additions, net 12,217,371 8,480,000 3,737,371 Conversions/payments (18,929,415 ) (18,929,415 ) - Loss on issuance of convertible notes 3,609,944 3,609,944 - Change in fair value (12,487,400 ) (5,756,787 ) (6,730,613 ) Fair value, December 31, 2022 $ 4,513,925 $ 4,203,579 $ 310,346
Federal Grants	Federal Grants In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse awarded the Company a research and development grant related to the development of its MPAR TM 5.4 3.2 2.2 1.1 5.1 2.1 3.0 2.8 2.8 10.7 In September 2019, the NIH/National Institute on Drug Abuse awarded the Company a second research and development grant related to the development of its TAAP/MPAR TM 5.4 The Company recognizes revenue when costs related to the grants are incurred. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with The revenue recognized under the MPAR Grant and OUD Grant was as follows: SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS 2022 2021 Year Ended December 31, 2022 2021 MPAR $ 2,006,885 $ 2,646,579 TAAP/OUD 516,498 884,620 Total $ 2,523,383 $ 3,531,199 Revenue $ 2,523,383 $ 3,531,199 Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation allowances are recorded. Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements
Immaterial Correction of an Error	Immaterial Correction of an Error In August 2022, the Company concluded that there was an error in the measurement of the unbilled receivable as of December 31, 2021. The error was corrected in the second quarter of 2022. The change resulted in a decrease in the balance of the unbilled receivable of $ 214,308 The Company, in consultation with the Audit Committee of the Board of Directors, evaluated the effect of these adjustments on the Company’s consolidated financial statements under ASC 250, Accounting Changes and Error Corrections and Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements and determined it was not necessary to recall its previously issued consolidated financial statements as the errors did not materially misstate any previously issued consolidated financial statements and the correction of the error in the current fiscal year is also not material. The Company looked at both quantitative and qualitative characteristics of the required corrections in making the determination.
Research and Development Costs	Research and Development Costs The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.
General and Administrative Expenses	General and Administrative Expenses General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees.
Stock-based Compensation	Stock-based Compensation The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. For the year ended December 31, 2022 and 2021, stock-based compensation costs are recorded in research and development and general and administrative expenses in the consolidated statements of operations. From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying equity awards.
Income Taxes	Income Taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements
Earnings per Share	Earnings per Share The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the Company’s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding during the period, determined using the treasury stock method and the average stock price during the period. A reconciliation of the numerators and denominators of the basic and diluted earnings per share calculations follows: SCHEDULE OF EARNINGS PER SHARE RECONCILIATION 2022 2021 Year Ended December 31, 2022 2021 Numerator: Net income (loss) attributable to common stockholders $ (25,085,496 ) $ (29,886,851 ) Denominator: Weighted average shares outstanding, basic and diluted 179,925 84,018 Net loss per share attributable to common stockholders, basic and diluted $ (139.42 ) $ (355.72 ) The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price for the Convertible Notes for the purposes of the weighted average share calculation below): SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES 2022 2021 Year Ended December 31, 2022 2021 Stock options 26,302 18,742 RSUs 3,772 - Warrants 138,485 42,807 Convertible Notes 73,326 2,533 Total 241,885 64,082 Anti-dilutive weighted average shares 241,885 64,082
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance is effective for fiscal years beginning after December 31, 2021 and interim periods within that year. Early adoption is permitted. The Company adopted the guidance in 2022 and it did not have a material impact on the financial statements due to their current tax position. In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Topic 470) to address issues identified as a result of the complexity with applying GAAP for certain financial instruments with characteristics of liabilities and equity. The FASB decided to reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Certain types of convertible instruments will continue to be subject to separation models: (a) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (b) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. For convertible instruments, the contracts primarily affected are those with beneficial conversions or cash conversion features as the accounting models for those specific features have been removed. For contracts in an entity’s own equity, the contracts primarily affected are freestanding instruments and embedded features that are accounted for as derivatives due to a failure to meet the settlement conditions of the derivatives scope exceptions. The FASB simplified the settlement assessment by removing the requirements to (a) consider whether the contract would be settled in registered shares, (b) to consider whether collateral is required to be posted, and (c) assess shareholder rights. The FASB also decided to enhance information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023 and early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company will adopt the standard with an effective date of January 1, 2023 and it is not expected to have a material impact on currently recorded transactions. In May 2021, the FASB issued ASU No. 2021-04, Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (A Consensus of the FASB Emerging Issues Task Force (the “EITF”)) – to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. Under the amendments, an issuer should measure the effect of a modification as the difference between the fair value of the modified warrant and the fair value of that warrant immediately before modification. The EITF concluded that the recognition of the modification depends on the nature of the transaction in which a warrant is modified. If there is more than one element in a transaction (for example, if the modification involves both a debt modification and an equity issuance), then the guidance requires the issuer to allocate the effect of the option modification to each element. On January 1, 2022, the Company adopted ASU 2021-04 and the adoption did not have a significant impact on the consolidated financial statements. Reclassification of prior year presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. An adjustment has been made to the consolidated statement of operations for the year ended December 31, 2021, to reclassify the loss on debt conversions.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE	The following tables present assets and liabilities measured and recorded at fair value on the Company’s consolidated balance sheet as of December 31, 2022 and 2021. As of December 31, 2021, all contingent put options, associated with the pre-combination convertible notes, were settled upon conversion of the notes at the closing of the Business Combination. SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE Total Level 1 Level 2 Level 3 December 31, 2022 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 4,203,579 $ - $ - $ 4,203,579 Liability classified warrants 310,346 310,346 Total $ 4,513,925 $ - $ - $ 4,513,925 Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements Total Level 1 Level 2 Level 3 December 31, 2021 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 16,799,837 $ - $ - $ 16,799,837 Liability classified warrants 3,303,588 - - 3,303,588 Total $ 20,103,425 $ - $ - $ 20,103,425
SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3	The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities for the year ended December 31, 2022: SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 For the year ended December 31, 2022 Total Convertible note Liability classified warrants Fair value, December 31, 2021 $ 20,103,425 $ 16,799,837 $ 3,303,588 Additions, net 12,217,371 8,480,000 3,737,371 Conversions/payments (18,929,415 ) (18,929,415 ) - Loss on issuance of convertible notes 3,609,944 3,609,944 - Change in fair value (12,487,400 ) (5,756,787 ) (6,730,613 ) Fair value, December 31, 2022 $ 4,513,925 $ 4,203,579 $ 310,346
SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS	The revenue recognized under the MPAR Grant and OUD Grant was as follows: SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS 2022 2021 Year Ended December 31, 2022 2021 MPAR $ 2,006,885 $ 2,646,579 TAAP/OUD 516,498 884,620 Total $ 2,523,383 $ 3,531,199 Revenue $ 2,523,383 $ 3,531,199
SCHEDULE OF EARNINGS PER SHARE RECONCILIATION	SCHEDULE OF EARNINGS PER SHARE RECONCILIATION 2022 2021 Year Ended December 31, 2022 2021 Numerator: Net income (loss) attributable to common stockholders $ (25,085,496 ) $ (29,886,851 ) Denominator: Weighted average shares outstanding, basic and diluted 179,925 84,018 Net loss per share attributable to common stockholders, basic and diluted $ (139.42 ) $ (355.72 )
SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES	The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive (the Company has utilized the principal balance outstanding and the end of period conversion price for the Convertible Notes for the purposes of the weighted average share calculation below): SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES 2022 2021 Year Ended December 31, 2022 2021 Stock options 26,302 18,742 RSUs 3,772 - Warrants 138,485 42,807 Convertible Notes 73,326 2,533 Total 241,885 64,082 Anti-dilutive weighted average shares 241,885 64,082

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS	Prepaid expenses and other current assets consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS 2022 2021 December 31, 2022 2021 Prepaid research and development $ 1,300,473 $ 2,124,008 Prepaid insurance 445,583 733,234 Other prepaid expenses 101,425 74,173 Total prepaid expenses and other current assets $ 1,847,481 $ 2,931,415

ACCRUED EXPENSES AND OTHER LI_2

ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES	Accrued expenses and other liabilities consisted of the following: SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES 2022 2021 December 31, 2022 2021 Accrued research and development $ 1,332,713 $ 388,997 Share subscription facility commitment fees 400,000 800,000 Professional fees 421,530 138,086 Other accrued liabilities 72,251 67,939 Accrued scientific advisory board fees - 60,032 Consultant fees - 1,342,479 Bonus Accrual - 610,000 Total accrued expenses and other liabilities $ 2,226,494 $ 3,407,533
SCHEDULE OF OTHER LONG-TERM LIABILITIES	Other long-term liabilities consisted of the following: SCHEDULE OF OTHER LONG-TERM LIABILITIES 2022 2021 December 31, 2022 2021 Share subscription facility commitment fees $ - $ 349,202 Liability classified warrants 310,346 3,303,588 Total other long-term liabilities $ 310,346 $ 3,652,790 Other long-term liabilities $ 310,346 $ 3,652,790

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2022
Short-Term Debt [Line Items]
SCHEDULE OF DEBT	The following table provides a summary of the Company’s outstanding debt as of December 31, 2022: SCHEDULE OF DEBT Principal balance Accrued interest Fair value adjustment Net debt balance 2022 Notes $ 3,905,264 $ 10,544 $ 287,771 $ 4,203,579 Financed insurance 195,273 7,906 - 203,179 Total $ 4,100,537 $ 18,450 $ 287,771 $ 4,406,758 The following table provides a summary of the Company’s outstanding debt as of December 31, 2021: Principal balance Accrued interest Unamortized debt discount Net debt balance 2021 Notes $ 13,647,341 $ 159,435 $ 2,993,061 $ 16,799,837 Financed insurance 385,187 4,082 - 389,269 Total $ 14,032,528 $ 163,517 $ 2,993,061 $ 17,189,106
SCHEDULE OF INTEREST EXPENSE DEBT	The interest expense recognized for notes payable (excluding the 2022 and 2021 Notes) was as follows: SCHEDULE OF INTEREST EXPENSE DEBT 2022 2021 Year Ended December 31, 2022 2021 Stated interest accrual $ 9,909 $ 251,857 Debt discount amortization - 945,969 Total $ 9,909 $ 1,197,826
SCHEDULE OF CONVERSION DEBT	The following table provides a summary of the Company’s 2021 Note conversions during the year ended December 31, 2022: SCHEDULE OF CONVERSION DEBT Shares Weighted Average Conversion Price Conversion Value During the year ended December 31, 2022 70,773 $ 191.06 $ 13,521,834
2022 Notes [Member]
Short-Term Debt [Line Items]
SCHEDULE OF CONVERSION DEBT	The following table provides a summary of the Company’s 2022 Notes conversions during the year ended December 31, 2022: SCHEDULE OF CONVERSION DEBT Weighted Average Conversion Shares Conversion Price Value During the year ended December 31, 2022 111,226 $ 36.06 $ 4,011,035

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
SCHEDULE OF OUTSTANDING WARRANT	On December 31, 2022, outstanding warrants to purchase shares of common stock are as follows: SCHEDULE OF OUTSTANDING WARRANT Reference Shares Underlying Outstanding Warrants Exercise Price Description Classification (a) 70,969 $ 2,400 .00– 2,760.00 LACQ warrants Equity (b) 4,608 $ 8.58 Share subscription facility Equity (c) 4,512 $ 187.20 2021 Notes Liability (d) 38,894 $ 24.07 2022 Notes Liability (e) 549,987 $ 16.80 Public offering Equity 668,970 a) On June 30, 2021, as a result of the Closing, the Company assumed a total of 78,751 7,782 2,400.00 2,760.00 June 30, 2026 41,666 29,303 On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the price of 2,083 2,760.00 2,400.00 56,590 b) On July 2, 2021, upon public listing of the Company’s shares, the Company issued 4,608 three 2,402.40 3,477.60 11.6 Ensysce Biosciences, Inc. Notes to the Consolidated Financial Statements The warrants have been subject to multiple exercise price reductions as required by a down round adjustment feature of the warrant, due to common stock issued at a price below the then current exercise price (primarily the result of the conversions of the 2021 Notes and the 2022 Notes). The adjustments have progressed from the original exercise price of $2,402.40 16.80 c) On September 24, 2021 and November 5, 2021, the Company issued 1,504 3,008 1,831.20 September 23, 2026 187.20 d) On July 1, 2022 and August 9, 2022, the Company issued 19,447 170.04 June 29, 2027 August 8, 2027 e) On December 9, 2022, the Company issued 549,987 16.80 December 9, 2027
SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS	The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows: SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS Stock price Exercise price Expected term (years) Volatility Risk free rate (a) LACQ warrants (grant date varies) 3,477.60 2,400.00 - 2,760.00 3.00 110.0 % 0.5 % (b) Share subscription facility (grant date 7/2/21) 3,477.60 2,402.40 3.00 110.0 % 0.5 % (b) Share subscription facility (remeasurement date varies) 1 4.40 - 1,029.60 16.80 - 1,080.00 1.56 - 2.49 108.2 125.3 % 1.0 4.5 % (c) Liability classified warrants (grant date 9/24/21) 1,077.60 1,831.20 5.00 94.1 % 1.0 % (c) Liability classified warrants (grant date 11/5/21) 540.00 1,831.20 5.00 94.1 % 1.0 % (c) Liability classified warrants (remeasured at 12/31/22) 9.36 187.20 3.75 - 3.85 140.9 141.1 % 4.2 % (d) Liability classified warrants (grant date 7/1/22) 136.80 170.04 5.00 98.9 % 2.9 % (d) Liability classified warrants (grant date 8/9/22) 127.20 170.04 5.00 102.8 % 3.0 % (d) Liability classified warrants (remeasured at 12/31/22) 9.36 24.12 4.50 - 4.61 138.0 139.4 % 4.0 %

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
SCHEDULE OF STOCK OPTION ACTIVITY	The following table summarizes the Company’s stock option activity during the year ended December 31, 2022: SCHEDULE OF STOCK OPTION ACTIVITY Weighted average Options Exercise price Remaining contractual life Intrinsic value Outstanding at December 31, 2021 18,505 $ 576.70 6.00 $ 10,207,306 Granted 9,535 928.11 8.34 - Exercised - - - - Expired / Forfeited (1,706 ) 519.62 - - Outstanding at December 31, 2022 26,334 707.63 6.53 - Exercisable at December 31, 2022 23,258 738.89 6.19 - Vested and expected to vest 26,334 707.63 6.53 -
SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS	The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (there were no grants issued in 2021): SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS December 31, 2022 Exercise price $ 102.00 1,507.20 Expected stock price volatility 76.61 95.87 % Expected term (years) 5.19 10.00 Risk-free interest rate 1.52 3.14 % Expected dividend yield 0 %
SCHEDULE OF RESTRICTED STOCK UNITS	The following table summarizes the Company’s restricted stock units activity during the year ended December 31, 2022: SCHEDULE OF RESTRICTED STOCK UNITS Restricted Stock Units Weighted average fair value Outstanding at December 31, 2021 - $ - Granted 5,320 215.22 Released (3,485 ) 294.29 Cancelled (832 ) - Outstanding at December 31, 2022 1,003 $ 120.02
SCHEDULE OF COMMON STOCK FUTURE ISSUANCE	The following shares of common stock are reserved for future issuance: SCHEDULE OF COMMON STOCK FUTURE ISSUANCE December 31, 2022 Awards outstanding under the 2021 Omnibus Incentive Plan 27,337 Awards available for future grant under 2021 Omnibus Incentive Plan 4,569 2022 Notes outstanding 162,232 Warrants outstanding 668,970 Total shares of common stock reserved for future issuance 863,108

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
SCHEDULE OF INCOME TAXES BENEFIT	Loss before provision for income taxes consisted of the following: SCHEDULE OF INCOME TAXES BENEFIT Year ending December 31, 2022 2021 United States $ (24,207,685 ) $ (29,145,901 )
SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT)	The federal and state income tax provision (benefit), included in general and administrative expenses in the Consolidated Statement of Operations, is summarized as follows: SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT) Year ending December 31, 2022 2021 Current state provision - $ 1,600
SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION	The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows: SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION Year ending December 31, 2022 2021 Income (benefit) taxes at statutory rates (5,083,614 ) (6,120,640 ) State income tax, net of federal benefit (175,164 ) (131,962 ) Warrants and convertible debt (234,214 ) 1,620,341 Nondeductible executive compensation - 480,248 Stock based compensation 303,499 (278,940 ) Share subscription facility transaction costs 20,335 2,664,850 Research and development tax credits (1,028,988 ) (501,451 ) Change in tax rates 54,263 371,784 Other (78,227 ) (139,213 ) Change in valuation allowance 6,222,110 2,034,983 Total - -
SCHEDULE OF DEFERRED TAX ASSETS	The Company’s deferred tax assets were comprised of the following: SCHEDULE OF DEFERRED TAX ASSETS As of December 31, 2022 2021 Deferred tax assets: Net operating loss tax carryforwards $ 26,726,066 $ 25,068,127 Tax credits 4,164,187 3,164,799 Capitalized research costs 3,729,483 - Stock-based compensation 1,173,158 915,675 Other 265,677 687,422 Deferred Tax Assets, Gross 36,058,571 29,836,023 Valuation allowance (36,052,644 ) (29,830,534 ) Total deferred tax assets 5,927 5,489 Deferred tax liabilities: Convertible notes: embedded derivatives - - Other (5,927 ) (5,489 ) Total deferred tax liabilities (5,927 ) (5,489 ) Net deferred tax assets $ - $ -
SUMMARY OF INCOME TAX CONTINGENCIES	The following table summarizes the activity related to the Company’s unrecognized tax benefits: SUMMARY OF INCOME TAX CONTINGENCIES Year ending December 31, 2022 2021 Balance at beginning of year 1,135,179 968,445 Increases related to current year tax positions 341,108 171,977 Decreases related to prior year tax positions (48,026 ) (5,243 ) Balance at end of year 1,428,261 1,135,179

ORGANIZATION AND PRINCIPAL AC_2

ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative) - $ / shares	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Jan. 31, 2021	Jun. 30, 2020
Common stock, par value	$ 0.0001		$ 0.0001
Debt instrument, conversion price	$ 0.06585
Common Stock, Shares Authorized	250,000,000	250,000,000	150,000,000	150,000,000
Preferred Stock, Shares Authorized	1,500,000		1,500,000	1,500,000
Preferred Stock, Par or Stated Value Per Share	$ 0.0001		$ 0.0001	$ 0.0001
Former Ensysce [Member]
Ownership percentage					71.80%
Former Ensysce [Member]
Debt instrument, conversion price					$ 0.06585
EBIR, Inc [Member]
Equity Method Investment, Ownership Percentage						79.20%
EBIR, Inc [Member] | Key Personnel [Member]
Equity Method Investment, Ownership Percentage						19.80%
EBIR, Inc [Member] | Unrelated Party [Member]
Equity Method Investment, Ownership Percentage						1%
Former Ensysce [Member]
Common stock, par value					$ 0.0001
EBIR, Inc [Member]
Common stock, par value						$ 0.001
Common Stock, Shares Authorized						1,000,000
Preferred Stock, Shares Authorized						100,000
Preferred Stock, Par or Stated Value Per Share						$ 0.001

BASIS OF PRESENTATION (Details

BASIS OF PRESENTATION (Details Narrative) - USD ($)

1 Months Ended

12 Months Ended

Oct. 28, 2022

Aug. 31, 2022

Jul. 31, 2022

Jun. 30, 2021

Dec. 31, 2022

Dec. 31, 2021

Dec. 09, 2022

Aug. 09, 2022

Nov. 05, 2021

Sep. 24, 2021

Jul. 02, 2021

Dec. 31, 2020

Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]

Reverse stock split

1-for-20 reverse split

Cash

$ 7,800,000

Prepaid expense

$ 1,100,000

Debt Instrument, conversion price

$ 0.06585

Accumulated deficit

$ 110,931,063

$ 85,845,567

Common stock, subscriptions value

$ 60,000,000

Warrants issued shares

78,751

549,987

19,447

3,008

1,504

4,608

Warrant, exercise price

$ 16.80

$ 16.80

$ 170.04

$ 1,831.20

$ 1,831.20

Proceeds from Convertible Debt

$ 8,480,000

$ 7,533,915

$ 14,029,842

July 2022 [Member] | Common Stock [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]

Commitment fees

$ 800,000

January 2023 [Member] | Common Stock [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]

Commitment fees

$ 400,000

Investor [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]

Warrants issued shares

4,608

Warrant, exercise price

$ 2,402.40

$ 16.80

Commitment fees

$ 1,200,000

Investor [Member] | First Anniversary [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]

Commitment fees

800,000

Investor [Member] | 18-Month Anniversary [Member]

Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]

Commitment fees

$ 400,000

SCHEDULE OF ASSETS AND LIABILIT

SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Fair value of convertible note	$ 4,203,579	$ 16,799,837
Liability classified warrants	310,346	3,303,588
Total	4,513,925	20,103,425
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of convertible note
Liability classified warrants
Total
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of convertible note
Liability classified warrants
Total
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of convertible note	4,203,579	16,799,837
Liability classified warrants	310,346	3,303,588
Total	$ 4,513,925	$ 20,103,425

SCHEDULE OF CHANGE IN FAIR VALU

SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 20,103,425
Additions, net	12,217,371
Conversions/payments	(18,929,415)
Loss on issuance of convertible notes	3,609,944
Change in fair value	(12,487,400)
Ending balance	4,513,925
Convertible Notes [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	16,799,837
Additions, net	8,480,000
Conversions/payments	(18,929,415)
Loss on issuance of convertible notes	3,609,944
Change in fair value	(5,756,787)
Ending balance	4,203,579
Liability Classified Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	3,303,588
Additions, net	3,737,371
Conversions/payments
Loss on issuance of convertible notes
Change in fair value	(6,730,613)
Ending balance	$ 310,346

SCHEDULE OF REVENUE RECOGNIZATI

SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Product Information [Line Items]
Revenue	$ 2,523,383	$ 3,531,199
M P A R [Member]
Product Information [Line Items]
Revenue	2,006,885	2,646,579
TAAP/OUD [Member]
Product Information [Line Items]
Revenue	$ 516,498	$ 884,620

SCHEDULE OF EARNINGS PER SHARE

SCHEDULE OF EARNINGS PER SHARE RECONCILIATION (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Numerator:
Net income (loss) attributable to common stockholders	$ (25,085,496)	$ (29,886,851)
Denominator:
Weighted average shares outstanding, basic and diluted	179,925	84,018
Net loss per share attributable to common stockholders, basic and diluted	$ (139.42)	$ (355.72)

SCHEDULE OF WEIGHTED AVERAGE SH

SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive weighted average shares	241,885	64,082
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive weighted average shares	26,302	18,742
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive weighted average shares	3,772
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive weighted average shares	73,326	2,533

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2019	Aug. 31, 2019	Sep. 30, 2018
Property, Plant and Equipment [Line Items]
Depreciation expense			$ 151
Proceeds from issuance of debt	$ 8,500,000		$ 15,900,000
Grants receivable					$ 10,700,000	$ 5,400,000	$ 5,100,000	$ 5,400,000
Unbilled receivables				$ 214,308
Year 1 [Member]
Property, Plant and Equipment [Line Items]
Grants receivable							2,100,000	3,200,000
Contribution of grants								1,100,000
Year 2 [Member]
Property, Plant and Equipment [Line Items]
Grants receivable							$ 3,000,000	$ 2,200,000
Year 3 [Member]
Property, Plant and Equipment [Line Items]
Grants receivable					$ 2,800,000
Year 4 [Member]
Property, Plant and Equipment [Line Items]
Grants receivable				$ 2,800,000
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives		5 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives		6 years

SCHEDULE OF PREPAID EXPENSES AN

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid research and development	$ 1,300,473	$ 2,124,008
Prepaid insurance	445,583	733,234
Other prepaid expenses	101,425	74,173
Total prepaid expenses and other current assets	$ 1,847,481	$ 2,931,415

SCHEDULE OF ACCRUED EXPENSES AN

SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued research and development	$ 1,332,713	$ 388,997
Share subscription facility commitment fees	400,000	800,000
Professional fees	421,530	138,086
Other accrued liabilities	72,251	67,939
Accrued scientific advisory board fees		60,032
Consultant fees		1,342,479
Bonus Accrual		610,000
Total accrued expenses and other liabilities	$ 2,226,494	$ 3,407,533

SCHEDULE OF OTHER LONG-TERM LIA

SCHEDULE OF OTHER LONG-TERM LIABILITIES (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Other long-term liabilities	$ 310,346	$ 3,652,790
Commitment Fees [Member]
Other long-term liabilities		349,202
Liability Classified Warrants [Member]
Other long-term liabilities	$ 310,346	$ 3,303,588

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 09, 2022	Aug. 09, 2022	Nov. 05, 2021	Sep. 24, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Contractual obligation		$ 21,600,000
Operating Lease, Payments		27,316
Payments for Rent		$ 31,756	$ 41,418
Annual bonus target percentage		7,500%
Annual bonus amount for future		$ 400,000
Warrant, exercise price		$ 16.80		$ 16.80	$ 170.04	$ 1,831.20	$ 1,831.20
Consultant compensation expenses			$ 1,342,479
Investors [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Common stock issuable upon exercise warrants	2,083
Warrant, exercise price	$ 1,507.20
Shares issued, share based compensation shares	208
Stock issued, restricted stock shares	833
Vesting period	1 year
Share based payment award, vesting rights, percentage	50%

SCHEDULE OF DEBT (Details)

SCHEDULE OF DEBT (Details) - USD ($)	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Principal balance	$ 4,100,537		$ 14,032,528
Accrued interest	18,450		163,517
Fair value adjustment	287,771
Net debt balance	4,406,758		17,189,106
Fair value adjustment			2,993,061
2022 Notes [Member]
Short-Term Debt [Line Items]
Principal balance	3,905,264
Accrued interest	10,544
Fair value adjustment	287,771
Net debt balance	4,203,579	$ 4,240,000
Fair value adjustment		$ 500,000
Financed Insurance [Member]
Short-Term Debt [Line Items]
Principal balance	195,273		385,187
Accrued interest	7,906		4,082
Fair value adjustment
Net debt balance	$ 203,179		389,269
Fair value adjustment
2021 Notes [Member]
Short-Term Debt [Line Items]
Principal balance			13,647,341
Accrued interest			159,435
Net debt balance			16,799,837
Fair value adjustment			$ 2,993,061

SCHEDULE OF INTEREST EXPENSE DE

SCHEDULE OF INTEREST EXPENSE DEBT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Stated interest accrual	$ 9,909	$ 251,857
Debt discount amortization		945,969
Total	$ 9,909	$ 1,197,826

SCHEDULE OF CONVERSION DEBT (De

SCHEDULE OF CONVERSION DEBT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022
Short-Term Debt [Line Items]
Weighted Average Conversion Price	$ 0.06585
2021 Notes [Member] | Note One [Member]
Short-Term Debt [Line Items]
Debt Instrument, Convertible, Conversion Date	Dec. 31, 2022
Shares	70,773
Weighted Average Conversion Price	$ 191.06
Conversion Value	$ 13,521,834
2022 Notes [Member]
Short-Term Debt [Line Items]
Weighted Average Conversion Price		$ 130.80
2022 Notes [Member] | Note One [Member]
Short-Term Debt [Line Items]
Debt Instrument, Convertible, Conversion Date	Dec. 31, 2022
Shares	111,226
Weighted Average Conversion Price	$ 36.06
Conversion Value	$ 4,011,035

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative)						1 Months Ended		12 Months Ended		15 Months Ended
	Aug. 08, 2022 $ / shares shares	Jun. 30, 2022 USD ($) Tradingdays $ / shares	Jun. 30, 2022 USD ($) $ / shares	Nov. 05, 2021 USD ($) $ / shares	Sep. 24, 2021 USD ($) $ / shares	Aug. 31, 2022 USD ($)	Jul. 31, 2022 USD ($) $ / shares	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($)	Mar. 31, 2023 USD ($)	Dec. 09, 2022 $ / shares	Oct. 10, 2022 USD ($)	Sep. 30, 2022 $ / shares	Aug. 09, 2022 $ / shares	Aug. 03, 2021 $ / shares	Jun. 30, 2021 $ / shares
Short-Term Debt [Line Items]
Proceeds from convertible debt						$ 8,480,000		$ 7,533,915	$ 14,029,842
Debt instrument, conversion price | $ / shares								$ 0.06585
Notes payable								$ 4,406,758	17,189,106
Cash proceeds from issuance of debt							$ 8,500,000		15,900,000
Original issue discount									2,993,061
Change in fair value of convertible notes								$ (5,756,787)	2,993,060
Original issue discount rate percentage								8%
Conversion of stock amount converted								$ 200,000
Warrants exercise price | $ / shares				$ 1,831.20	$ 1,831.20			$ 16.80			$ 16.80			$ 170.04
Financed insurance premiums								$ 399,949	867,300
Financed insurance premiums outstanding								203,179
Interest expense								109,525	1,295,307
Financed Insurance Premiums [Member]
Short-Term Debt [Line Items]
Interest expense								$ 7,905
Financed Insurance Premiums [Member] | Forecast [Member]
Short-Term Debt [Line Items]
Interest expense										$ 9,402
Maximum [Member]
Short-Term Debt [Line Items]
Warrants exercise price | $ / shares															$ 2,760	$ 2,760
Minimum [Member]
Short-Term Debt [Line Items]
Warrants exercise price | $ / shares															$ 2,400	$ 2,400
2021 Notes [Member]
Short-Term Debt [Line Items]
Convetible debt				$ 10,600,000	$ 5,300,000
Proceeds from convertible debt				$ 9,400,000	$ 4,600,000
Debt maturity date				Aug. 04, 2023	Jun. 23, 2023
Debt instrument, interest rate								5%
Debt instrument original issue discount								6%
Payments of debt issuance costs								$ 15,900,000
Debt issuance costs, net								1,900,000
Legal fees								1,000,000
Amortization of financing costs								$ 900,000
Percentage of cash settlement premium								8%
Interest expense after consideration of conversion								$ 200,000
Chnage in fair value								2,700,000
Notes payable									16,799,837
Original issue discount									$ 2,993,061
Warrants exercise price | $ / shares	$ 187.20
2021 Notes [Member] | Other Operating Income (Expense) [Member]
Short-Term Debt [Line Items]
Loss on debt conversions								4,000,000
Debt conversions								1,000,000
Remaining notes payable												$ 400,000
2021 Notes [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument, conversion price | $ / shares	187.20												$ 55.20
2021 Notes [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument, conversion price | $ / shares	$ 84												$ 84
2022 Notes [Member]
Short-Term Debt [Line Items]
Convetible debt		$ 8,000,000	$ 8,000,000
Debt instrument, conversion price | $ / shares		$ 130.80	$ 130.80
Notes payable		$ 4,240,000	$ 4,240,000					4,203,579
Cash proceeds from issuance of debt		4,000,000
Initial fair value		12,090,000	12,090,000
Loss on issuance of fair value		3,600,000
Issuance costs		$ 1,100,000
Original issue discount rate		6%
Original issue discount		$ 500,000	$ 500,000
Legal and investment banking fees		$ 600,000
Change in fair value of convertible notes								$ 3,100,000
Original issue discount rate percentage								6%
Common stock average price percentage			0.10
Debt conversion description			The Company may elect to pay all or part of the redemption amount in cash with a premium of 8% or in conversion shares of common stock based on a conversion price equal to the lesser of (i) the conversion price and (ii) 92% of the average of the three lowest VWAPs (as defined) during the ten consecutive trading days ending on the trading day that is immediately prior to the applicable redemption date, but in no event may the Company pay the redemption amount in conversion shares of common stock unless the conversion price is at least equal to $24.072 and the Company has been in compliance with customary requirements under the agreement, unless waived in writing by the holder.
Warrants to purchase common stock | shares	19,447
Warrants exercise price | $ / shares	$ 170.04						$ 187.20
Percenatge of premium conversion price	30%
Debt term	5 years
Convertible debt								$ 5,000,000
Debt interest rate								6%
2022 Notes [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Debt instrument, conversion price | $ / shares		$ 0.92	$ 0.92
Trading days | Tradingdays		10
2022 Notes [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt maturity date								Feb. 07, 2024
Debt instrument, redemption price, percentage								20%
2022 Notes [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt maturity date								Dec. 29, 2023

SCHEDULE OF OUTSTANDING WARRANT

SCHEDULE OF OUTSTANDING WARRANT (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	668,970
Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	70,969	[1]
Warrant description	LACQ warrants	[1]
Warrant One [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price | $ / shares	$ 2,400	[1]
Warrant One [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price | $ / shares	$ 2,760	[1]
Warrant Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	4,608	[2]
Exercise price | $ / shares	$ 8.58	[2]
Warrant description	Share subscription facility	[2]
Warrant Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	4,512	[3]
Exercise price | $ / shares	$ 187.20	[3]
Warrant description	2021 Notes	[3]
Warrant Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	38,894	[4]
Exercise price | $ / shares	$ 24.07	[4]
Warrant description	2022 Notes	[4]
Warrant Five [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	549,987	[5]
Exercise price | $ / shares	$ 16.80	[5]
Warrant description	Public offering	[5]
[1]On June 30, 2021, as a result of the Closing, the Company assumed a total of 78,751 7,782 2,400.00 2,760.00 June 30, 2026 41,666 29,303 4,608 three 2,402.40 3,477.60 11.6 1,504 3,008 1,831.20 September 23, 2026 187.20 19,447 170.04 June 29, 2027 August 8, 2027 549,987 16.80 December 9, 2027

SCHEDULE OF OUTSTANDING WARRA_2

SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical) - USD ($)

12 Months Ended

Aug. 03, 2021

Jul. 02, 2021

Jun. 30, 2021

Dec. 31, 2022

Dec. 31, 2021

Dec. 09, 2022

Aug. 09, 2022

Aug. 08, 2022

Jul. 31, 2022

Jul. 02, 2022

Nov. 05, 2021

Sep. 24, 2021

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants issued

4,608

78,751

549,987

19,447

3,008

1,504

Warrants cancelled

7,782

Warrants, exercise price

$ 16.80

$ 16.80

$ 170.04

$ 1,831.20

$ 1,831.20

Warrant expiration date

Jun. 30, 2026

Aug. 08, 2027

Jun. 29, 2027

Sep. 23, 2026

Class of warrant or right, outstanding

549,987

Fair value adjustment of warrants

$ 11,565,472

Warrant term

3 years

5 years

2022 Notes [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 170.04

$ 187.20

General and Administrative Expense [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 2,402.40

Fair value adjustment of warrants

$ 11,600,000

Grant date fair value of warrants price per share

$ 3,477.60

Subscription Arrangement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants issued

2,083

Subscription Arrangement [Member] | General and Administrative Expense [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Fair value adjustment of warrants

$ 56,590

Public Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Class of warrant or right, outstanding

41,666

Private Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Remaining of cashless warrant shares

29,303

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants issued

549,987

Warrants, exercise price

$ 16.80

Warrant expiration date

Dec. 09, 2027

Class of warrant or right, outstanding

59,523

Minimum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 2,400

$ 2,400

Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 2,760

$ 2,760

SCHEDULE OF WARRANTS FAIR VALUE

SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS (Details)	Dec. 31, 2022 $ / shares	Dec. 09, 2022	Aug. 09, 2022 $ / shares	Jul. 01, 2022 $ / shares	Nov. 05, 2021 $ / shares	Sep. 24, 2021 $ / shares	Jul. 02, 2021 $ / shares
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years		5 years					3 years
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	3,477.60
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	2,400
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	2,760
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	3 years						3 years
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	110
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	0.5
Share Subscription Facility [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants							3,477.60
Share Subscription Facility [Member] | Measurement Input, Share Price [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.40
Share Subscription Facility [Member] | Measurement Input, Share Price [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1,029.60
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants							2,402.40
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	16.80
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1,080
Share Subscription Facility [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1
Expected term years	1 year 6 months 21 days
Share Subscription Facility [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.5
Expected term years	2 years 5 months 26 days
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants							110
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	108.2
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	125.3
Share Subscription Facility [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants							0.5
Liability Classified Warrants Grant Date [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants			127.20	136.80	540	1,077.60
Liability Classified Warrants Grant Date [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants			170.04	170.04	1,831.20	1,831.20
Liability Classified Warrants Grant Date [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years			5 years	5 years	5 years	5 years
Liability Classified Warrants Grant Date [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants			102.8	98.9	94.1	94.1
Liability Classified Warrants Grant Date [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants			3	2.9	1	1
Liability Classified Warrants Remeasured [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	9.36
Liability Classified Warrants Remeasured [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	187.20
Liability Classified Warrants Remeasured [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	3 years 9 months
Liability Classified Warrants Remeasured [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	3 years 10 months 6 days
Liability Classified Warrants Remeasured [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	140.9
Liability Classified Warrants Remeasured [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	141.1
Liability Classified Warrants Remeasured [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.2
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	9.36
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	24.12
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	4 years 6 months
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	4 years 7 months 9 days
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	138
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	139.4
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($) $ / shares in Units, $ in Millions			1 Months Ended
	Dec. 09, 2022	Jun. 30, 2021	Jan. 31, 2021	Dec. 31, 2022	Sep. 30, 2022	Aug. 09, 2022	Dec. 31, 2021	Nov. 05, 2021	Sep. 24, 2021	Jul. 02, 2021
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized		150,000,000		250,000,000	250,000,000		150,000,000
Preferred stock, shares authorized		1,500,000		1,500,000			1,500,000
Preferred stock par value		$ 0.0001		$ 0.0001			$ 0.0001
Preferred stock, shares issued				0			0
Preferred stock, shares outstanding				0			0
Common stock, shares, issued				534,571			102,759
Common stock, shares outstanding		25,913		534,490			102,678
Stock issued to settlement of convertible debt		5,658
Stock issued to settlement amount of convertible debt		$ 5.8
Common stock issued to settlement of termination agreement			2,083
Common stock issued to settelment of underwriting costs		520
Exercise price	$ 16.80
Underwriting fees	$ 0.3
Warrants issued	549,987	78,751				19,447		3,008	1,504	4,608
Warrant, exercise price	$ 16.80			$ 16.80		$ 170.04		$ 1,831.20	$ 1,831.20
Warrants and rights outstanding term	5 years									3 years
Transaction costs	$ 0.5
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Stock issued during period shares issued for services	241,666
Exercise price	$ 16.80
Stock issued during period value issued for services	$ 4.1
Former Ensysce [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, shares, issued		66,889
Stock issued during period shares purchase of assets		81

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Option outstanding, beginning balance | shares	18,505
Weighted average exercise price. beginning balance	$ 576.70
Weighted average remaining contractual term, beginning balance	6 years
Aggregate intrinsic value, beginning balance | $	$ 10,207,306
Option outstanding, granted | shares	9,535
Weighted average exercise price, granted	$ 928.11
Weighted average remaining contractual term, grants	8 years 4 months 2 days
Aggregate intrinsic value, granted
Option outstanding, exercised | shares
Weighted average exercise price, exercised
Aggregate intrinsic value, exercised | $
Option outstanding, Expired or Forfeited | shares	(1,706)
Weighted average exercise price, expired / forfeited	$ 519.62
Aggregate intrinsic value, expired or forfeited | $
Option outstanding, ending balance | shares	26,334
Weighted average exercise price, ending balance	$ 707.63
Weighted average remaining contractual term, ending balance	6 years 6 months 10 days
Aggregate intrinsic value, ending balance | $
Option, exercisable | shares	23,258
Weighted average exercise price, exercisable	$ 738.89
Weighted average remaining contractual term, exercisable	6 years 2 months 8 days
Aggregate intrinsic value, beginning balance | $
Option vested or expected to vest | shares	26,334
Weighted average exercise price, vested or expected to vest	$ 707.63
Weighted average remaining contractual term in years, vested and expected to vest	6 years 6 months 10 days
Aggregate intrinsic value, vested or expected to vest | $

SCHEDULE OF SHARE-BASED PAYMENT

SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected stock price volatility, minimum	76.61%
Expected stock price volatility, maximum	95.87%
Risk-free interest rate, minimum	1.52%
Risk-free interest rate, maximum	3.14%
Expected dividend rate	0%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 102
Expected term (years)	5 years 2 months 8 days
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 1,507.20
Expected term (years)	10 years

SCHEDULE OF RESTRICTED STOCK UN

SCHEDULE OF RESTRICTED STOCK UNITS (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock units outstanding, beginning balance | shares
Weight average fair value, beginning balance | $ / shares
Restricted stock units, granted | shares	5,320
Weight average fair value, granted | $ / shares	$ 215.22
Restricted stock units, released | shares	(3,485)
Weight average fair value, released | $ / shares	$ 294.29
Restricted stock units, cancelled | shares	(832)
Weight average fair value, cancelled | $ / shares
Restricted stock units outstanding, ending balance | shares	1,003
Weight average fair value, ending balance | $ / shares	$ 120.02

SCHEDULE OF COMMON STOCK FUTURE

SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)	Dec. 31, 2022 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	863,108
Warrant Outstanding [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	668,970
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	27,337
Share-Based Payment Arrangement, Option [Member] | Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	4,569
Share-Based Payment Arrangement, Option [Member] | 2022 Notes Outstanding [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	162,232

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Jan. 26, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option, outstanding	26,334	18,505
Stock reserved for future issuance	863,108
Number of restricted stock granted	9,535
Exercise price per share vested	$ 707.63
Weighted-average fair value per share , grant	$ 230.89
Unrecognized stock based compensation	$ 361,863
Weighted average period	1 year 7 months 9 days
Board of Members [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of restricted stock granted	114,550
Board of Members [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option, vesting period	0 years
Exercise price per share vested	$ 8.50
Board of Members [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option, vesting period	4 years
Exercise price per share vested	$ 125.60
General and Administrative Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation expense	$ 919,056	$ 121,764
Research and Development Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation expense	$ 152,787	$ 0
2021 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option, outstanding	18,432
Stock reserved for future issuance	4,166		12,500

SCHEDULE OF INCOME TAXES BENEFI

SCHEDULE OF INCOME TAXES BENEFIT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
UNITED STATES
Income (loss) before provision for income taxes	$ (24,207,685)	$ (29,145,901)

SCHEDULE OF FEDERAL AND STATE I

SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Current state provision		$ 1,600

SCHEDULE OF FEDERAL INCOME TAX

SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income (benefit) taxes at statutory rates	$ (5,083,614)	$ (6,120,640)
State income tax, net of federal benefit	(175,164)	(131,962)
Warrants and convertible debt	(234,214)	1,620,341
Nondeductible executive compensation		480,248
Stock based compensation	303,499	(278,940)
Share subscription facility transaction costs	20,335	2,664,850
Research and development tax credits	(1,028,988)	(501,451)
Change in tax rates	54,263	371,784
Other	(78,227)	(139,213)
Change in valuation allowance	6,222,110	2,034,983
Total

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Net operating loss tax carryforwards	$ 26,726,066	$ 25,068,127
Tax credits	4,164,187	3,164,799
Capitalized research costs	3,729,483
Stock-based compensation	1,173,158	915,675
Other	265,677	687,422
Deferred Tax Assets, Gross	36,058,571	29,836,023
Valuation allowance	(36,052,644)	(29,830,534)
Total deferred tax assets	5,927	5,489
Convertible notes: embedded derivatives
Other	(5,927)	(5,489)
Total deferred tax liabilities	(5,927)	(5,489)
Net deferred tax assets

SUMMARY OF INCOME TAX CONTINGEN

SUMMARY OF INCOME TAX CONTINGENCIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Balance at beginning of year	$ 1,135,179	$ 968,445
Increases related to current year tax positions	341,108	171,977
Decreases related to prior year tax positions	(48,026)	(5,243)
Balance at end of year	$ 1,428,261	$ 1,135,179

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2018	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Tax Credit Carryforward, Description	carryforward indefinitely and be available to offset up to 80% of future taxable income each year.
Unrecognized tax benefits that would impact effective tax rate	$ 1,400,000	$ 1,100,000
Financing receivable accrued interest write off	0	$ 0
California Franchise Tax Board [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	73,200,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	102,900,000		$ 20,500,000	$ 82,400,000
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit carryforward amount	4,200,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Tax credit carryforward amount	1,500,000
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit carryforward amount	$ 1,700,000

RELATED PARTIES (Details Narrat

RELATED PARTIES (Details Narrative) - USD ($)		1 Months Ended			12 Months Ended
	Dec. 09, 2022	Oct. 31, 2022	Aug. 31, 2022	Jul. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Proceeds from Convertible Debt			$ 8,480,000		$ 7,533,915	$ 14,029,842
Purchase of shares		3,838
Settlement of restricted stock units					3,783,240
Share price	$ 16.80
Warrants in public offering	549,987
Warrant [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Purchase of shares	29,761
Share price	$ 16.80
Warrants in public offering	59,523
IPO [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Purchase of shares	241,666,000,000
Share price	$ 16.80
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Cash compensation					0	30,909
Accounts Payable					$ 0	$ 12,989
Board of Directors Chairman [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Proceeds from Convertible Debt							$ 2,500,000
Chief Executive Officer And Board Member [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Purchase of shares				3,838
Settlement of restricted stock units				$ 800,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)

12 Months Ended

Mar. 23, 2023

Feb. 02, 2023

Jan. 31, 2023

Jan. 12, 2023

Jan. 03, 2023

Oct. 28, 2022

Dec. 31, 2022

May 12, 2023

Mar. 31, 2023

Dec. 09, 2022

Aug. 09, 2022

Dec. 31, 2021

Nov. 05, 2021

Sep. 24, 2021

Jul. 02, 2021

Jun. 30, 2021

Subsequent Event [Line Items]

Debt instrument, conversion price

$ 0.06585

Common stock, shares issued

534,571

102,759

Repayment of convertible debt

$ 1,408,364

Net debt balance

$ 4,406,758

$ 17,189,106

Warrant, exercise price

$ 16.80

$ 16.80

$ 170.04

$ 1,831.20

$ 1,831.20

Warrants exercisable

549,987

19,447

3,008

1,504

4,608

78,751

Warrant term

5 years

3 years

Stockholders equity reverse stock split

1-for-20 reverse split

Warrant [Member]

Subsequent Event [Line Items]

Warrant, exercise price

$ 16.80

Warrants exercisable

549,987

Subsequent Event [Member]

Subsequent Event [Line Items]

Net debt balance

$ 600,000

Sale of stock number of shares issued in transaction

297,619

Sale of stock price per share

$ 10.08

Sale of stock consideration received per transaction

$ 3,000,000

Sale of stock transaction date

Feb. 06, 2023

Warrant, exercise price

$ 12.60

Warrants exercisable

297,619

Warrants issued

20,832

Warrant term

5 years

Stockholders equity reverse stock split

On March 23, 2023, at a special meeting of stockholders, the Company’s stockholders approved a proposal to authorize the Company’s Board of Directors to complete a reverse stock split at a ratio of not less than one-for-five and not more than one-for-twelve. On March 31, 2023, the Company completed a one-for-twelve reverse split of its outstanding common stock

Subsequent Event [Member] | Warrant [Member]

Subsequent Event [Line Items]

Warrant, exercise price

$ 8.58

Subsequent Event [Member] | Series A Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred stock voting rights

the Board of Directors declared a dividend of 0.012 of a share of Series A Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company’s common stock to stockholders of record on February 13, 2023. Each full share of the Series A Preferred Stock entitles holders to 1,000,000 votes per share with respect to the reverse stock split proposal and the adjournment proposal at the Company’s special meeting of stockholders on March 23, 2023. The Series A Preferred Stock has no dividend rights and is subject to full redemption following the effectiveness of a reverse stock split. The Series A Preferred Stock was registered through a Certificate of Designation filed with the State of Delaware on February 1, 2023.

Subsequent Event [Member] | 2022 Notes [Member]

Subsequent Event [Line Items]

Common stock, shares issued

400,000

Repayment of convertible debt

3,100,000

Repayments of notes payable

$ 400,000

Subsequent Event [Member] | Letter Agreement [Member] | 2022 Notes [Member]

Subsequent Event [Line Items]

Debt instrument, conversion price

$ 24.072

$ 9.0144

GEM Yield Bahamas Limited [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Stock repurchased during period shares

44,444

Stock repurchased during period value

$ 400,000